Brainstorm Cell Therapeutics (BCLI) Misses Q4 EPS by 3c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge